Immupharma has reported a preclinical study on P140 conducted in a MASH model.
Further details on the study results were not immediately available.
Immupharma Reports Preclinical Study on P140 in MASH Model
Immupharma has released findings from a preclinical study evaluating its P140 candidate in a MASH disease model.
PA
Priya Anand · Equities & Earnings Desk · 15 Sept 2026 · 08:02 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
